Future potential biomarkers for postinterventional restenosis and accelerated atherosclerosis

Biomarkers in Medicine

Volumn 6, Issue 1, 2012, Pages 53-66

  Karper, Jacco C ^a   Ewing, Mark M ^a   Jukema, J Wouter ^a   Quax, Paul H A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

atherosclerosis; damage associated molecular patterns; inflammation; innate immunity

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 10; LIPOCORTIN 5; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; PHOSPHORYLCHOLINE; RANTES; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY BLOOD LEVEL; ANTIBODY TITER; APOPTOSIS; ARTERY RESISTANCE; ATHEROSCLEROSIS; BARE METAL STENT; CARDIOVASCULAR RISK; CELL STRESS; DISEASE MARKER; DISEASE SEVERITY; DRUG ELUTING STENT; HUMAN; HYPERSENSITIVITY REACTION; IN-STENT RESTENOSIS; INFLAMMATION; METAL IMPLANTATION; MOLECULAR INTERACTION; NONHUMAN; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RESTENOSIS; REVIEW; TISSUE INJURY; UPREGULATION;

ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CONSTRICTION, PATHOLOGIC; HUMANS; POSTOPERATIVE COMPLICATIONS;

EID: 84856591740     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.11.107     Document Type: Review

References (106)

1. Niccoli G, Montone RA, Ferrante G, Crea F. The evolving role of inflammatory biomarkers in risk assessment after stent implantation. J. Am. Coll. Cardiol. 56, 1783-1793 (2010).
2. Wang TJ, Gona P, Larson MG, et al. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. N. Engl. J. Med. 355, 2631-2639 (2006).
3. Dahlof B. Cardiovascular disease risk factors: epidemiology and risk assessment. Am. J. Cardiol. 105, 3A-9A (2010).
4. Andersson J, Libby P, Hansson GK. Adaptive immunity and atherosclerosis. Clin. Immunol. 134, 33-46 (2010).
5. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352, 1685-1695 (2005).
6. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 473, 317-325 (2011).
7. Tabas I. Apoptosis and efferocytosis in mouse models of atherosclerosis. Curr. Drug Targets 8, 1288-1296 (2007).
8. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J. Am. Coll. Cardiol. 54, 2129-2138 (2009).
9. van der Hoeven BL, Pires NM, Warda HM, et al. Inflammation in atherosclerosis: from pathophysiology to practice. Int. J. Cardiol. 99, 9-17 (2005).
10. Farooq V, Gogas BD, Serruys PW. Restenosis: delineating the numerous causes of drug-eluting stent restenosis. Circ. Cardiovasc. Interv. 4, 195-205 (2011).
11. Garg S, Serruys PW. Coronary stents: current status. J. Am. Coll. Cardiol. 56, S1-S42 (2010).
12. Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. In-stent restenosis in the drug-eluting stent era. J. Am. Coll. Cardiol. 56, 1897-1907 (2010).
13. Weintraub WS. The pathophysiology and burden of restenosis. Am. J. Cardiol. 100, 3K-9K (2007).
14. Pires NM, Jukema JW, Daemen MJ, Quax PH. Drug-eluting stents studies in mice: do we need atherosclerosis to study restenosis? Vascul. Pharmacol. 44, 257-264 (2006).
15. Newby AC. Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc. Res. 69, 614-624 (2006). (Pubitemid 43140745)
16. van Hinsbergh VW, Engelse MA, Quax PH. Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler. Thromb. Vasc. Biol. 26, 716-728 (2006). (Pubitemid 43732143)
17. Jukema JW, Verschuren JJ, Ahmed TA, Quax PH. Restenosis after PCI. Part 1: pathophysiology and risk factors. Nat. Rev. Cardiol. 9, 53-62 (2011).
18. Jukema JW, Ahmed TA, Verschuren JJ, Quax PH. Restenosis after PCI. Part 2: prevention and therapy. Nat. Rev. Cardiol. doi:10.1038/ nrcardio.2011.148 (2011) (Epub ahead of print).
19. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 113, 2335-2362 (2006). (Pubitemid 43947980)
20. Sukhija R, Fahdi I, Garza L, et al. Inflammatory markers, angiographic severity of coronary artery disease, and patient outcome. Am. J. Cardiol. 99, 879-884 (2007). (Pubitemid 46483272)
21. Walter DH, Fichtlscherer S, Sellwig M, et al. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J. Am. Coll. Cardiol. 37, 839-846 (2001). (Pubitemid 32202453)
22. Ferrante G, Niccoli G, Biasucci LM, et al. Association between C-reactive protein and angiographic restenosis after bare metal stents: an updated and comprehensive meta-analysis of 2747 patients. Cardiovasc. Revasc. Med. 9, 156-165 (2008). (Pubitemid 351910724)
23. Walter DH, Fichtlscherer S, Britten MB, et al. Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation. J. Am. Coll. Cardiol. 38, 2006-2012 (2001). (Pubitemid 33116578)
24. Aronson D. Inflammatory markers: linking unstable plaques to coronary event, an interventional perspective. Int. J. Cardiovasc. Intervent. 6, 110-118 (2004). (Pubitemid 39665425)
25. Ware JH. The limitations of risk factors as prognostic tools. N. Engl. J. Med. 355, 2615-2617 (2006). (Pubitemid 44969120)
26. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11, 373-384 (2010).
27. Miyake K. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin. Immunol. 19, 3-10 (2007). (Pubitemid 46498750)
28. Boersma HH, Kietselaer BL, Stolk LM, et al. Past, present, and future of annexin A5: from protein discovery to clinical applications. J. Nucl. Med. 46, 2035-2050 (2005). (Pubitemid 46657451)
29. Cederholm A, Frostegard J. Annexin A5 as a novel player in prevention of atherothrombosis in SLE and in the general population. Ann. NY Acad. Sci. 1108, 96-103 (2007). (Pubitemid 47528722)
30. van Genderen HO, Kenis H, Hofstra L, Narula J, Reutelingsperger CP. Extracellular annexin A5: functions of phosphatidylserine-binding and two-dimensional crystallization. Biochim. Biophys. Acta 1783, 953-963 (2008).
31. Cederholm A, Frostegard J. Annexin A5 multitasking: a potentially novel antiatherothrombotic agent? Drug News Perspect. 20, 321-326 (2007). (Pubitemid 47345224)
32. Cederholm A, Frostegard J. Annexin A5 in cardiovascular disease and systemic lupus erythematosus. Immunobiology 210, 761-768 (2005). (Pubitemid 41683860)
33. Ewing MM, de Vries MR, Nordzell M, et al. Annexin A5 therapy attenuates vascular inflammation and remodeling and improves endothelial function in mice. Arterioscler. Thromb. Vasc. Biol. 31, 95-101 (2011).
34. van Tits LJ, van Heerde WL, van der Vleuten GM, et al. Plasma annexin A5 level relates inversely to the severity of coronary stenosis. Biochem. Biophys. Res. Commun. 356, 674-680 (2007).
35. Hofstra L, Heymans S. Annexin A5 and the failing heart; lost or found in translation? Eur. Heart J. 28, 2695-2696 (2007). (Pubitemid 350135542)
36. Michelsen KS, Wong MH, Shah PK, et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc. Natl Acad. Sci. USA 101, 10679-10684 (2004). (Pubitemid 38955802)
37. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat. Immunol. 12, 204-212 (2011).
38. Hansson GK, Lundberg AM. Toll in the vessel wall: for better or worse? Proc. Natl Acad. Sci. USA 108, 2637-2638 (2011).
39. Ionita MG, Arslan F, de Kleijn DP, Pasterkamp G. Endogenous inflammatory molecules engage Toll-like receptors in cardiovascular disease J. Innate Immun. 2, 307-315 (2010).
40. Andonegui G, Kerfoot SM, McNagny K, Ebbert KV, Patel KD, Kubes P. Platelets express functional Toll-like receptor 4. Blood 106, 2417-2423 (2005). (Pubitemid 41510815)
41. Hollestelle SC, de Vries MR, van Keulen JK, et al. Toll-like receptor 4 is involved in outward arterial remodeling. Circulation 109, 393-398 (2004). (Pubitemid 38139309)
42. Karper JC, de Vries MR, van den Brand BT, et al. Toll-like receptor 4 is involved in human and mouse vein graft remodeling, and local gene silencing reduces vein graft disease in hypercholesterolemic apoE*3 Leiden mice. Arterioscler. Thromb. Vasc. Biol. 31, 1033-1040 (2011).
43. Vink A, Schoneveld AH, van der Meer JJ, et al. In vivo evidence for a role of Toll-like receptor 4 in the development of intimal lesions. Circulation 106, 1985-1990 (2002). (Pubitemid 35176306)
44. Stewart CR, Stuart LM, Wilkinson K, et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat. Immunol. 11, 155-161 (2010).
45. Park JS, Gamboni-Robertson F, He Q, et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am. J. Physiol. Cell Physiol. 290, C917-C924 (2006).
46. Yu M, Wang H, Ding A, et al. HMGB1 signals through Toll-like receptor (TLR) 4 and TLR2. Shock 26, 174-179 (2006). (Pubitemid 44162504)
47. Gondokaryono SP, Ushio H, Niyonsaba F, et al. The extra domain A of fibronectin stimulates murine mast cells via Toll-like receptor 4. J. Leukoc. Biol. 82, 657-665 (2007). (Pubitemid 47367158)
48. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev. Immunol. 5, 331-342 (2005). (Pubitemid 40516158)
49. Abraham E, Arcaroli J, Carmody A, Wang H, Tracey KJ. HMG-1 as a mediator of acute lung inflammation. J. Immunol. 165, 2950-2954 (2000).
50. Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice Science 285, 248-251 (1999). (Pubitemid 29329996)
51. Park JS, Svetkauskaite D, He Q, et al. Involvement of Toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem. 279, 7370-7377 (2004). (Pubitemid 38294612)
52. Kalinina N. Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines. Arterioscler. Thromb. Vasc. Biol. 24, 2320-2325 (2004). (Pubitemid 39658036)
53. Kohno T, Anzai T, Naito K, et al. Role of high-mobility group box 1 protein in post-infarction healing process and left ventricular remodelling. Cardiovasc. Res. 81, 565-573 (2009).
54. Kohno T, Anzai T, Shimizu H, et al. Impact of serum high-mobility group box 1 protein elevation on oxygenation impairment after thoracic aortic aneurysm repair. Heart Vessels 26, 306-312 (2011).
55. Leelahavanichkul A, Huang Y, Hu X, et al. Chronic kidney disease worsens sepsis and sepsis-induced acute kidney injury by releasing high mobility group box protein-1. Kidney Int. 80(11), 1198-1211 (2011).
56. Urbonaviciute V, Voll RE. HMGB1 represents a potential marker of disease activity and novel therapeutic target in SLE. J. Intern. Med. 270(4), 309-318 (2011).
57. Ito T, Kawahara K, Nakamura T, et al. High-mobility group box 1 protein promotes development of microvascular thrombosis in rats. J. Thromb. Haemost. 5, 109-116 (2007). (Pubitemid 44921075)
58. Okamura Y, Watari M, Jerud ES, et al. The extra domain A of fibronectin activates Toll-like receptor 4. J. Biol. Chem. 276, 10229-10233 (2001).
59. Tan MH, Sun Z, Opitz SL, et al. Deletion of the alternatively spliced fibronectin EIIIA domain in mice reduces atherosclerosis. Blood 104, 11-18 (2004). (Pubitemid 38879830)
60. Lasarte JJ, Casares N, Gorraiz M, et al. The extra domain A from fibronectin targets antigens to TLR4-expressing cells and induces cytotoxic T cell responses in vivo. J. Immunol. 178, 748-756 (2007). (Pubitemid 46098855)
61. Arslan F, Smeets MB, Riem Vis PW, et al. Lack of fibronectin-EDA promotes survival and prevents adverse remodeling and heart function deterioration after myocardial infarction. Circ. Res. 108, 582-592 (2011).
62. Babaev VR, Porro F, Linton MF, Fazio S, Baralle FE, Muro AF. Absence of regulated splicing of fibronectin EDA exon reduces atherosclerosis in mice. Atherosclerosis 197, 534-540 (2008). (Pubitemid 351417892)
63. Takaoka M, Uemura S, Kawata H, et al. Inflammatory response to acute myocardial infarction augments neointimal hyperplasia after vascular injury in a remote artery. Arterioscler. Thromb. Vasc. Biol. 26, 2083-2089 (2006). (Pubitemid 44253792)
64. Krasinski K, Spyridopoulos I, Kearney M, Losordo DW. In vivo blockade of tumor necrosis factor-alpha accelerates functional endothelial recovery after balloon angioplasty. Circulation 104, 1754-1756 (2001). (Pubitemid 32963337)
65. Rectenwald JE, Moldawer LL, Huber TS, Seeger JM, Ozaki CK. Direct evidence for cytokine involvement in neointimal hyperplasia. Circulation 102, 1697-1702 (2000).
66. Monraats PS, Pires NM, Schepers A, et al. Tumor necrosis factor-alpha plays an important role in restenosis development. FASEB J. 19, 1998-2004 (2005). (Pubitemid 41759745)
67. Parmar JH, Aslam M, Standfield NJ. Percutaneous transluminal angioplasty of lower limb arteries causes a systemic inflammatory response. Ann. Vasc. Surg. 23, 569-576 (2009).
68. Kubica J, Kozinski M, Krzewina-Kowalska A, et al. Combined periprocedural evaluation of CRP and TNF-alpha enhances the prediction of clinical restenosis and major adverse cardiac events in patients undergoing percutaneous coronary interventions. Int. J. Mol. Med. 16, 173-180 (2005).
69. Rogers C, Welt FG, Karnovsky MJ, Edelman ER. Monocyte recruitment and neointimal hyperplasia in rabbits. Coupled inhibitory effects of heparin. Arterioscler. Thromb. Vasc. Biol. 16, 1312-1318 (1996). (Pubitemid 26339721)
70. Egashira K, Zhao Q, Kataoka C, et al. Importance of monocyte chemoattractant protein-1 pathway in neointimal hyperplasia after periarterial injury in mice and monkeys. Circ. Res. 90, 1167-1172 (2002). (Pubitemid 34786901)
71. Roque M, Kim WJ, Gazdoin M, et al. CCR2 deficiency decreases intimal hyperplasia after arterial injury. Arterioscler. Thromb. Vasc. Biol. 22, 554-559 (2002). (Pubitemid 34408733)
72. Schepers A, Eefting D, Bonta PI, et al. Anti-MCP-1 gene therapy inhibits vascular smooth muscle cells proliferation and attenuates vein graft thickening both in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 26, 2063-2069 (2006). (Pubitemid 44253789)
73. Eefting D, Bot I, de Vries M, et al. Local lentiviral short hairpin RNA silencing of CCR2 inhibits vein graft thickening in hypercholesterolemicapolipoprotein E3-Leiden mice. J. Vasc. Surg. 50, 152-160 (2009).
74. Korybalska K, Pyda M, Grajek S, Lanocha M, Breborowicz A, Witowski J. Serum profiles of monocyte chemoattractant protein-1 as a biomarker for patients recovering from myocardial infarction. Clin. Res. Cardiol. 99, 315-322 (2010).
75. de Lemos JA, Morrow DA, Sabatine MS, et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 107, 690-695 (2003). (Pubitemid 36222595)
76. Sako H, Miura S, Iwata A, et al. Changes in CCR2 chemokine receptor expression and plasma MCP-1 concentration after the implantation of bare metal stents versus sirolimus-eluting stents in patients with stable angina. Intern. Med. 47, 7-13 (2008).
77. Oshima S, Ogawa H, Hokimoto S, et al. Plasma monocyte chemoattractant protein-1 antigen levels and the risk of restenosis after coronary stent implantation. Jpn Circ. J. 65, 261-264 (2001).
78. Eefting D, Schepers A, de Vries MR, et al. The effect of interleukin-10 knock-out and overexpression on neointima formation in hypercholesterolemic apoE*3-Leiden mice. Atherosclerosis 193, 335-342 (2007). (Pubitemid 47058121)
79. Feldman LJ, Aguirre L, Ziol M, et al. Interleukin-10 inhibits intimal hyperplasia after angioplasty or stent implantation in hypercholesterolemic rabbits. Circulation 101, 908-916 (2000). (Pubitemid 30117887)
80. Monraats PS, Kurreeman FA, Pons D, et al. Interleukin 10: a new risk marker for the development of restenosis after percutaneous coronary intervention. Genes Immun. 8, 44-50 (2007). (Pubitemid 46158102)
81. Zurakowski A, Wojakowski W, Dzielski T, et al. Plasma levels of C-reactive protein and interleukin-10 predict late coronary in-stent restenosis 6 months after elective stenting. Kardiol. Pol. 67, 623-630 (2009).
82. Hong SJ, Kim ST, Kim TJ, et al. Cellular and molecular changes associated with inhibitory effect of pioglitazone on neointimal growth in patients with Type 2 diabetes after zotarolimus-eluting stent implantation. Arterioscler. Thromb. Vasc. Biol. 30, 2655-2665 (2010).
83. Schober A, Manka D, von Hundelshausen P, et al. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation 106, 1523-1529 (2002).
84. Inami N, Nomura S, Manabe K, Kimura Y, IwasakaT. Platelet-derived chemokine RANTES may be a sign of restenosis after percutaneous coronary intervention in patients with stable angina pectoris. Platelets 17, 565-570 (2006). (Pubitemid 44837726)
85. Satoh D, Inami N, Shimazu T, et al. Soluble TRAIL prevents RANTES-dependent restenosis after percutaneous coronary intervention in patients with coronary artery disease. J. Thromb. Thrombolysis 29, 471-476 (2010).
86. Vogiatzi K, Voudris V, Apostolakis S, et al. Genetic diversity of RANTES gene promoter and susceptibility to coronary artery disease and restenosis after percutaneous coronary intervention. Thrombosis Res. 124, 84-89 (2009).
87. Hartvigsen K, Chou MY, Hansen LF, et al. The role of innate immunity in atherogenesis. J. Lipid Res. 50(Suppl.), S388-S393 (2009).
88. Nilsson J, Nordin FG, Schiopu A, Shah PK, Jansson B, Carlsson R. Oxidized LDL antibodies in treatment and risk assessment of atherosclerosis and associated cardiovascular disease. Curr. Pharm. Des. 13, 1021-1030 (2007). (Pubitemid 46696558)
89. de Faire U, Frostegard J. Natural antibodies against phosphorylcholine in cardiovascular disease. Ann. NY Acad. Sci. 1173, 292-300 (2009).
90. Frantz S, Ertl G, Bauersachs J. Mechanisms of disease: Toll-like receptors in cardiovascular disease. Nat. Clin. Pract. Cardiovasc. Med. 4, 444-454 (2007). (Pubitemid 47180328)
91. Amabile N, Rautou PE, Tedgui A, Boulanger CM. Microparticles: key protagonists in cardiovascular disorders. Semin. Thromb. Hemost. 36, 907-916 (2010).
92. Chou MY, Fogelstrand L, Hartvigsen K, et al. Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans. J. Clin. Invest. 119, 1335-1349 (2009).
93. Binder CJ, Horkko S, Dewan A, et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat. Med. 9, 736-743 (2003). (Pubitemid 36749223)
94. Fiskesund R, Stegmayr B, Hallmans G, et al. Low levels of antibodies against phosphorylcholine predict development of stroke in a population-based study from northern Sweden. Stroke 41, 607-612 (2010).
95. Frostegard J. Low level natural antibodies against phosphorylcholine: a novel risk marker and potential mechanism in atherosclerosis and cardiovascular disease. Clin. Immunol. 134, 47-54 (2010).
96. Su J, Georgiades A, Wu R, Thulin T, de Faire U, Frostegard J. Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension. Atherosclerosis 188, 160-166 (2006). (Pubitemid 44160704)
97. de Faire U, Su J, Hua X, et al. Low levels of IgM antibodies to phosphorylcholine predict cardiovascular disease in 60-year old men: effects on uptake of oxidized LDL in macrophages as a potential mechanism. J. Autoimmun. 34, 73-79 (2010).
98. Leroyer AS, Tedgui A, Boulanger CM. Role of microparticles in atherothrombosis J. Intern. Med. 263, 528-537 (2008).
99. Dignat-George F, Boulanger CM. The many faces of endothelial microparticles Arterioscler. Thromb. Vasc. Biol. 31, 27-33 (2011).
100. Rautou PE, Vion AC, Amabile N, et al. Microparticles, vascular function, and atherothrombosis. Circ. Res. 109, 593-606 (2011).
101. Torzewski M, Rist C, Mortensen RF, et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler. Thromb. Vasc. Biol. 20, 2094-2099 (2000).
102. Ishikawa T, Hatakeyama K, Imamura T, et al. Involvement of C-reactive protein obtained by directional coronary atherectomy in plaque instability and developing restenosis in patients with stable or unstable angina pectoris. Am. J. Cardiol. 91, 287-292 (2003). (Pubitemid 36143867)
103. Nishi K, Itabe H, Uno M, et al. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler. Thromb. Vasc. Biol. 22, 1649-1654 (2002).
104. Bamberg F, Truong QA, Koenig W, et al. Differential associations between blood biomarkers of inflammation, oxidation, and lipid metabolism with varying forms of coronary atherosclerotic plaque as quantified by coronary CT angiography. Int. J. Cardiovasc. Imaging doi:10.1007/s10554- 010-9773-2 (2011) (Epub ahead of print).
105. Hellings WE, Moll FL, de Vries JP, et al. Atherosclerotic plaque composition and occurrence of restenosis after carotid endarterectomy. JAMA 299, 547-554 (2008). (Pubitemid 351214252)
106. de Kleijn DP, Moll FL, Hellings WE, et al. Local atherosclerotic plaques are a source of prognostic biomarkers for adverse cardiovascular events. Arterioscler. Thromb. Vasc. Biol. 30, 612-619 (2010).